Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for treatment-resistant myasthenia gravis
IRCT20190324043105N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in myasthenia gravis (MG), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Clinical status of the patients, Amount of daily activities in myasthenia gravis patients and 3 more. Started Jun 2019; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on IRCT20190324043105N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190324043105N2.